Dr Reddy's Laboratories Faces Semaglutide Supply Delay Due to API Issue
Dr Reddy's Laboratories announced a delay in commercial supplies of its semaglutide products due to out-of-specification batches linked to an active pharmaceutical ingredient (API) issue. The company is investigating the root cause and implementing corrective measures, assuring no impact on patient safety or global filings.